Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $0.90 and traded as high as $0.95. Brainstorm Cell Therapeutics shares last traded at $0.95, with a volume of 7,748 shares traded.

Brainstorm Cell Therapeutics Stock Performance

The business has a 50 day simple moving average of $0.98 and a 200-day simple moving average of $0.90. The firm has a market cap of $14.69 million, a price-to-earnings ratio of -0.31 and a beta of 0.28.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Friday, August 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). As a group, research analysts anticipate that Brainstorm Cell Therapeutics Inc. will post -3.01 earnings per share for the current year.

About Brainstorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc is a biotechnology company developing cell-based therapies for neurodegenerative diseases. The company’s lead platform, NurOwn, uses a patient’s own bone marrow-derived mesenchymal stem cells, which are processed to secrete neurotrophic factors and then administered back to the patient. BrainStorm has investigated NurOwn as a potential treatment for conditions involving neuronal damage and degeneration.

The company’s clinical development work has focused primarily on amyotrophic lateral sclerosis (ALS), as well as progressive multiple sclerosis and other neurodegenerative disorders.